94 related articles for article (PubMed ID: 15123732)
1. Chemotherapy for melanoma: the resultant of conflicting vectors.
Mitchell MS
J Clin Oncol; 2004 Jun; 22(11):2043-5. PubMed ID: 15123732
[No Abstract] [Full Text] [Related]
2. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
Lev DC; Onn A; Melinkova VO; Miller C; Stone V; Ruiz M; McGary EC; Ananthaswamy HN; Price JE; Bar-Eli M
J Clin Oncol; 2004 Jun; 22(11):2092-100. PubMed ID: 15123733
[TBL] [Abstract][Full Text] [Related]
3. Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
Roider E; Schneider J; Flaig MJ; Ruzicka T; Kunte C; Berking C
Int J Dermatol; 2012 Sep; 51(9):1142-4. PubMed ID: 21913905
[No Abstract] [Full Text] [Related]
4. [At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].
Bénard J
Bull Cancer; 1998 Jun; 85(6):520-1. PubMed ID: 9752277
[No Abstract] [Full Text] [Related]
5. Management of metastatic melanoma.
Tawbi HA; Kirkwood JM
Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
Nin-Asai R; Sawada M; Matsumoto T; Saito S; Yokota K; Akiyama M
J Dermatol; 2014 Feb; 41(2):178-9. PubMed ID: 24387309
[No Abstract] [Full Text] [Related]
7. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
9. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Treudler R; Georgieva J; Geilen CC; Orfanos CE
J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
11. Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
Wolf M; Eskerski H; Bauder-Wüst U; Haberkorn U; Eisenhut M
Melanoma Res; 2006 Dec; 16(6):487-96. PubMed ID: 17119449
[TBL] [Abstract][Full Text] [Related]
12. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model.
Tagne JB; Kakumanu S; Nicolosi RJ
Mol Pharm; 2008; 5(6):1055-63. PubMed ID: 19434855
[TBL] [Abstract][Full Text] [Related]
13. [Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Schmutz JL; Barbaud A; Trechot P
Ann Dermatol Venereol; 2006 May; 133(5 Pt 1):500. PubMed ID: 16760848
[No Abstract] [Full Text] [Related]
14. [Disseminated melanoma treatment].
Neidhardt-Bérard EM; Négrier S
Rev Prat; 2004 Jun; 54(11):1210-4. PubMed ID: 15496028
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic induced fascial oedema.
Lim I; Kefford R; Manolios N
Ann Rheum Dis; 2005 Jan; 64(1):162-3. PubMed ID: 15608322
[No Abstract] [Full Text] [Related]
16. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Eggermont AM; Kirkwood JM
Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
[TBL] [Abstract][Full Text] [Related]
18. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
19. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
20. Dacarbazine induced acute myeloid leukemia in melanoma.
Collins CM; Morgan DS; Mosse C; Sosman J
Melanoma Res; 2009 Oct; 19(5):337-40. PubMed ID: 19741425
[No Abstract] [Full Text] [Related]
[Next] [New Search]
